SILO PHARMA, INC. Unrealized Gain (Loss) on Investments
SILO PHARMA, INC. (SILO) reported Unrealized Gain (Loss) on Investments of $4.96 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2026-08-13
- SILO PHARMA, INC. unrealized gain (loss) on investments for the quarter ending 2026-06-30 was $4.96K.
- SILO PHARMA, INC. unrealized gain (loss) on investments for the quarter ending 2026-03-31 was -$2.06K, a 124.86% decline year-over-year.
- SILO PHARMA, INC. unrealized gain (loss) on investments for the quarter ending 2025-12-31 was -$12.17K.
- SILO PHARMA, INC. unrealized gain (loss) on investments for the quarter ending 2025-09-30 was $1.78K, a 84.87% decline year-over-year.
- SILO PHARMA, INC. unrealized gain (loss) on investments for fiscal 2023 was -$3.12K.
- SILO PHARMA, INC. unrealized gain (loss) on investments for fiscal 2022 was -$331.20K, a 233.23% decline from fiscal 2021.
- SILO PHARMA, INC. unrealized gain (loss) on investments for fiscal 2021 was $248.59K.
- SILO PHARMA, INC. unrealized gain (loss) on investments for fiscal 2020 was -$9.19K.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 3 month as first filed | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 6 month as first filed | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 9 month as first filed | Unrealized Gain (Loss) on Investments 12 month | Unrealized Gain (Loss) on Investments 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.96K 10-Q · filed 2026-08-13 | $2.90K 10-Q · filed 2026-08-13 | -$9.27K derived: sum of 3 quarters · filed 2026-08-13 | -$7.48K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$2.06K 10-Q · filed 2026-05-14 | -$14.23K derived: sum of 2 quarters · filed 2026-05-14 | -$12.45K derived: sum of 3 quarters · filed 2026-05-14 | -$13.59K derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2025-12-31 | -$12.17K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | -$10.38K derived: sum of 2 quarters · filed 2026-04-14 | -$11.53K derived: sum of 3 quarters · filed 2026-04-14 | -$3.24K POS AM · filed 2026-04-14 | ||||
| 2025-09-30 | $1.78K 10-Q · filed 2025-11-13 | $641.00 derived: sum of 2 quarters · filed 2025-11-13 | $8.93K 10-Q · filed 2025-11-13 | |||||
| 2025-06-30 | -$1.14K 10-Q · filed 2025-08-13 | $7.14K 10-Q · filed 2025-08-13 | ||||||
| 2025-03-31 | $8.29K derived: POS AM 12 month − 3 quarters · filed 2026-04-14 | |||||||
| 2024-09-30 | $11.77K 10-Q · filed 2025-11-13 | -$6.31K derived: sum of 2 quarters · filed 2025-11-13 | $26.02K 10-Q · filed 2025-11-13 | |||||
| 2024-06-30 | -$18.08K 10-Q · filed 2025-08-13 | $14.25K 10-Q · filed 2025-08-13 | ||||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $2.56K derived: sum of 2 quarters · filed 2025-03-28 | -$950.00 derived: sum of 3 quarters · filed 2025-03-28 | -$3.12K 10-K · filed 2025-03-28 | -$6.23K 10-K · filed 2024-03-25 | |||
| 2023-09-30 | $2.56K 10-Q · filed 2023-11-13 | -$950.00 derived: sum of 2 quarters · filed 2024-08-13 | -$3.12K 10-Q · filed 2024-11-12 | -$723.00 10-Q · filed 2023-11-13 | -$75.38K derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-06-30 | -$3.51K 10-Q · filed 2024-08-13 | -$8.52K 10-Q · filed 2023-08-11 | -$3.12K 10-Q · filed 2024-08-13 | -$3.28K 10-Q · filed 2023-08-11 | -$77.94K derived: sum of 3 quarters · filed 2024-08-13 | -$113.01K derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $390.00 10-Q · filed 2024-05-13 | $5.24K 10-Q · filed 2023-05-12 | -$74.43K derived: sum of 2 quarters · filed 2024-05-13 | -$109.50K derived: sum of 3 quarters · filed 2024-05-13 | -$169.01K derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | -$74.82K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$109.89K derived: sum of 2 quarters · filed 2023-03-24 | -$169.41K derived: sum of 3 quarters · filed 2023-03-24 | -$331.20K 10-K · filed 2023-03-24 | ||||
| 2022-09-30 | -$35.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$94.58K derived: sum of 2 quarters · filed 2022-11-10 | -$256.38K 10-Q · filed 2022-11-10 | -$377.42K derived: sum of 4 quarters · filed 2023-03-24 | ||||
| 2022-06-30 | -$59.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | -$221.31K 10-Q · filed 2022-08-01 | -$342.35K derived: sum of 3 quarters · filed 2023-03-24 | -$41.47K derived: sum of 4 quarters · filed 2023-03-24 | ||||
| 2022-03-31 | -$161.80K 10-Q · filed 2022-05-13 | -$282.84K derived: sum of 2 quarters · filed 2023-03-24 | $18.04K derived: sum of 3 quarters · filed 2023-03-24 | $48.04K derived: sum of 4 quarters · filed 2023-03-24 | ||||
| 2021-12-31 | -$121.04K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $179.84K derived: sum of 2 quarters · filed 2023-03-24 | $209.84K derived: sum of 3 quarters · filed 2023-03-24 | $248.59K 10-K · filed 2023-03-24 | ||||
| 2021-09-30 | $300.88K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $330.88K derived: sum of 2 quarters · filed 2022-11-10 | $369.63K 10-Q · filed 2022-11-10 | |||||
| 2021-06-30 | $30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | $68.75K 10-Q · filed 2022-08-01 | ||||||
| 2021-03-31 | $38.75K 10-Q · filed 2022-05-13 | |||||||
| 2020-12-31 | -$9.19K 10-K · filed 2022-03-28 | |||||||
| 2019-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-17 | -$117.85K derived: sum of 2 quarters · filed 2021-05-17 | -$218.68K derived: sum of 3 quarters · filed 2021-05-17 | -$170.19K 10-K/A · filed 2021-05-17 | ||||
| 2019-09-30 | -$117.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$218.68K derived: sum of 2 quarters · filed 2020-11-05 | -$170.19K 10-Q · filed 2020-11-05 | -$346.16K derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | -$100.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$52.34K 10-Q · filed 2020-08-14 | -$228.31K derived: sum of 3 quarters · filed 2020-08-14 | $277.88K derived: sum of 4 quarters · filed 2020-08-14 | ||||
| 2019-03-31 | $48.49K 10-Q · filed 2020-05-12 | -$127.48K derived: sum of 2 quarters · filed 2020-05-12 | $378.71K derived: sum of 3 quarters · filed 2020-05-12 | -$148.33K derived: sum of 4 quarters · filed 2020-05-12 | ||||
| 2018-12-31 | -$175.97K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | $330.22K derived: sum of 2 quarters · filed 2020-03-20 | -$196.82K derived: sum of 3 quarters · filed 2020-03-20 | -$278.68K 10-K · filed 2020-03-20 | ||||
| 2018-09-30 | $506.19K 10-Q · filed 2018-11-14 | -$20.86K derived: sum of 2 quarters · filed 2019-08-13 | -$102.71K 10-Q · filed 2019-11-13 | $278.80K derived: sum of 4 quarters · filed 2019-08-13 | ||||
| 2018-06-30 | -$527.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | -$608.90K 10-Q · filed 2019-08-13 | -$227.39K derived: sum of 3 quarters · filed 2019-08-13 | -$573.97K derived: sum of 4 quarters · filed 2019-08-13 | ||||
| 2018-03-31 | -$81.86K 10-Q · filed 2019-05-14 | $299.65K derived: sum of 2 quarters · filed 2019-05-14 | -$46.92K derived: sum of 3 quarters · filed 2019-05-14 | |||||
| 2017-12-31 | $381.51K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-04 | $34.93K derived: sum of 2 quarters · filed 2019-04-04 | $912.09K 10-K · filed 2019-04-04 | |||||
| 2017-09-30 | -$346.57K 10-Q · filed 2018-11-14 | $530.59K 10-Q · filed 2018-11-14 | ||||||
| 2013-12-31 | $65.14K 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |